Dual-Chamber Pacers Help Reduce Thromboembolic Event Risk - AHA Study
This article was originally published in The Gray Sheet
Use of dual-chamber in lieu of single-chamber pacemakers for ventricular pacing can lower platelet activation in the heart and reduce the risk of thromboembolic events, William Toff, MD, University of Leicester (UK) told attendees of the American Heart Association's scientific sessions Nov. 10 in Atlanta.
You may also be interested in...
Anticipated results from two early stage studies - the Mode Selection Trial (MOST) and the PAGE trial in the UK - will further support evidence to date that use of dual-chamber pacemakers is unnecessary in the majority of patients, according to Ronald Vliestra, MD, Watson Clinic, Lakeland, Florida.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.